Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02834884

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

All Tumor Types Neoplasms

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University Vienna - General Hospital AKH, Vienna, Austria

Loading trial locations.

About this study

Patients are recruited in the platform for the research purpose of 5 downstream projects. For more information, please have a look at the "Groups and cohorts" section.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Patients with pathologically confirmed selected tumor types (at site or centrally);
  • Mandatory availability of adequate human biological material (HBM);
  • Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
  • Age ≥ 12 years;
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
  • Written informed consent according to applicable legal and ethical requirements;

Treatment and study plan

RP-1828 IMMUcan

Genetic

WES, lcWGS and RNAseq, multiplex IF and IMC

RP-1759 AYA/TYA

Genetic

WES, RNAseq and EPIC array

RP-1843 Arcagen

Genetic

NGS panel

RP-1920 BioRadon

Genetic

NGS panel

2148 MRD

Genetic

ctDNA detection and WES

Primary outcomes

  1. To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care

    Time frame: 5 years

    material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Secondary outcomes

  1. To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future;

    Time frame: 5 years

  2. To investigate the molecular pathways related to the development of specific tumors from a biological point of view;

    Time frame: 5 years

  3. To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally;

    Time frame: 5 years

  4. To collect large series of homogeneous clinical data to analyse the disease course and treatment performed;

    Time frame: 5 years

  5. To investigate the prevalence and validate the prognostic or predictive value of novel biomarkers in cancers;

    Time frame: 5 years

  6. To perform biospecimen and data based high quality research aiming to facilitate the discovery of new test for tumor biomarkers or facilitate the establishment of validated tests for tumor biomarkers;

    Time frame: 5 years

  7. To identify patients with molecular alterations in their tumor that can be matched to biomarker-driven clinical trials, to facilitate enrollment of cancer patients in biomarker-driven clinical trials.

    Time frame: 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

EORTC HQ

CONTACT

[email protected]

+32 2 774 1611

Sponsors and collaborators

Lead sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Network

Registry information

Acronym: SPECTA

Important dates

Study start
2017
Primary completion
2022
Study completion
2031
First posted
Jul 15, 2016
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.